Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients.
Primary lymphoma of bone (PLB) is a very rare neoplasm. Many aspects of this entity have not been well defined or reported in Chinese population. The purpose of our study is to identify the prognostic factors of PLB. Twenty-five patients newly diagnosed with PLB were included in this retrospective study. The main pathologic subtype of PLB was diffuse large B-cell lymphoma (DLBCL), followed by anaplastic large-cell lymphoma. The pelvis was the most commonly involved site (13 cases, 52%). The 5-year overall survival (OS) rate was 55.0%. Cox regression analysis demonstrated that IPI score was an independent prognostic factor of survival (RR = 8.46, P = 0.013). The mean survival time (MST) was 90.3 months for patients with radiation and 54.0 months for those without radiotherapy (P = 0.033). Patients who received the anti-CD20 monoclonal antibody rituximab therapy showed a favorable survival trend, but not significant benefit (MST: 74.5 months vs. 68.6 months, P = 0.149). Some clinical characteristics in the Chinese population are different from those in westerners. The frequency of T-cell subtypes is higher, and the pelvis is the most commonly involved site. Irradiation plus chemotherapy may be better than chemotherapy alone. The role of bisphosphonates and rituximab in PLB therapy warrants further investigation.
Huang
Jia-Jia
JJ
State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China.
Xia
Yi
Y
Zhu
Ying-Jie
YJ
Lin
Tong-Yu
TY
Li
Zhi-Ming
ZM
Jiang
Wen-Qi
WQ
Xu
Rui-Hua
RH
Huang
Hui-Qiang
HQ
Lv
Yue
Y
Sun
Xiao-Fei
XF
Xia
Zhong-Jun
ZJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D044466:Asian People / Q000235:genetics*; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
Ann Oncol. 1997 Aug;8(8):727-37
9332679
Cases J. 2009 Jun 26;2:6384
19829800
Cancer. 1999 Mar 1;85(5):1166-78
10091803
Cancer Treat Rev. 2008;34 Suppl 1:S19-24
18486348
Jpn J Clin Oncol. 2007 Mar;37(3):216-23
17472971
Ann Oncol. 2007 Jan;18(1):129-135
17018705
J Clin Pathol. 2009 Sep;62(9):820-4
19734480
Cancer. 2006 Jun 15;106(12):2652-6
16700039
Int J Oncol. 2006 Jun;28(6):1571-5
16685458
Leuk Lymphoma. 2006 Jan;47(1):65-70
16321829
Aust N Z J Med. 1994 Dec;24(6):701-4
7717923
Ir J Med Sci. 2008 Sep;177(3):247-51
18516662
J Clin Oncol. 2007 Feb 10;25(5):579-86
17242396
Leukemia. 1999 Dec;13(12):2094-8
10602434
Leuk Lymphoma. 2008 Nov;49(11):2125-32
19021055
Eur J Haematol. 2006 Nov;77(5):365-71
16879606
J Cancer Res Clin Oncol. 2005 Mar;131(3):163-8
15605165
Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1087-93
9169817
Leuk Lymphoma. 2010 Jan;51(1):39-49
19860629